Interview with Dominique Amory, President, Lilly France
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
Address: 24 Boulevard Vital Bouhot
CS 50004
92521 Neuilly-sur-Seine Cedex
Tel: 01 55 49 34 34
Web: http://www.lilly.com/Pages/home.aspx
The Pharmaceutical company Lilly has been in France since 1962. This is the 4th subsidiary of Lilly after the United States, Japan and Germany.
Lilly France is the 16th French pharmaceutical company and has a turnover of 2.3 billion euros in 2008, including 1.6 billion under its manufacturing (factory Fegersheim).
Advancing medicine, contributing to major therapeutic advances, allowing everyone to live better and longer: this is the mission of the pharmaceutical company Lilly.
Eli Lilly and Company is a specialty pharmaceutical company entirely focused on innovation and committed to developing a portfolio of drugs to both the best and the first in their class, to allow patients to be healthier and live a longer and more active.
To do this, we use the results of recent medical studies in our laboratories pharmaceutical world. We are collaborating with eminent scientific organizations, and we appeal to the most advanced technological tools, while ensuring the high quality service to our customers.
Through internal programs and external initiatives, we intend to meet the most urgent medical needs. Lilly employs more than 40 450 people worldwide and markets its medicines in 143 countries. The company has major research and development centers in 9 countries and conducts clinical trials in over 50 countries.
Lilly’s drugs treat depression, schizophrenia, cancer, diabetes, osteoporosis and other disorders.
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
Pierre Banzet, President of Group Synerlab, one of the top ten French CMOs, discusses his group’s ambitious European expansion strategy, driven by their specialties in multi-dose, preservative-free eye drops, generics,…
The Director of the newly formed Necker Institute for Sick Children reveals how the inspiration behind INEM was to bring people together in order to create a common scientific policy…
Pfizer Global Established Products’ BU Head and Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well…
The Head of the Department of Medical Oncology at the Pitié-Salpêtrière Hospital reveals how France is the only country in the world with universal and unlimited access to healthcare, how…
(© Sébastien Borda) The CEO of Novartis France reveals how the construction of a new French headquarters demonstrates a commitment to develop operations in the country, how the Huningue Biotechnology…
The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association, reveals how the pharmaceutical industry worldwide has to take into account what is a fair…
The President of Fefis, and the recently elected President of Medicen Paris Region, a Paris-based business cluster, talks about the need to build the future of the French health economy, not…
The director of GEMME reveals how the French generics market is young in comparison to other European countries – where generics were on the market twenty years before they became…
The Chairman & CEO of DBV Technologies reveals how they have developed a new therapeutic method and new technology in the form of a patch to treat various allergies. DBV received…
The President of Cristers discusses the history of generic drugs in France and what steps can be taken to increase generics penetration, while also outlining the ‘cooperative’ business model behind…
Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a…
The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the…
See our Cookie Privacy Policy Here
